AOD-9604

What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to amino acids 177–191 of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus. It was developed to isolate the lipolytic (fat-burning) properties of growth hormone while avoiding the anabolic and growth-promoting effects that make full hGH problematic for fat-loss applications.

The peptide is believed to stimulate lipolysis (breakdown of fat cells) and inhibit lipogenesis (fat storage) through interactions with beta-3 adrenoceptors and possibly GH receptors. Unlike full HGH, it does not raise IGF-1 levels, does not affect blood glucose in a meaningful way, and does not promote cell proliferation.

AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA as a food ingredient in the early 2010s. However, this designation does not constitute approval as a pharmaceutical drug. It failed to meet endpoints in Phase 3 clinical trials for obesity (conducted by Metabolic Pharmaceuticals) and was not approved as a prescription medication.

What The Research Says

Animal studies demonstrated significant fat loss and lipolysis. Early human clinical trials showed modest results. Phase 2b and Phase 3 trials for obesity did not meet primary endpoints compared to placebo, which led to the drug's discontinuation as an obesity treatment. The evidence base is significantly weaker than GLP-1 agonists.

Some in vitro research suggests potential for cartilage repair and osteoarthritis, but this is very early-stage. The peptide continues to be offered in compounding contexts despite limited clinical evidence.

📚 Key Reference: PMID: 11146367 (early AOD-9604 research)

Common Uses

• Fat loss/lipolysis (off-label, research context)
• Body composition optimization (limited evidence)

Important Safety Information

In clinical trials, AOD-9604 appeared relatively safe with few significant adverse events at tested doses. However, the absence of clinical efficacy means the risk-benefit calculation is unfavorable compared to approved alternatives. Long-term safety data is limited. The main concern is purchasing unverified compounds from unregulated sources. Always consult your provider.

Questions To Ask Your Provider

1. What evidence supports AOD-9604 over FDA-approved weight loss medications?
2. What are the Phase 3 trial results showing and why did it fail to get approved?
3. Where is this peptide sourced and what quality testing has been done?
4. Are there any other medications this might interact with?

Regulatory Status

NOT FDA-approved as a pharmaceutical. Failed Phase 3 trials for obesity. Has GRAS status as a food ingredient only. Available through compounding pharmacies but without approved indication. Evidence base is limited.